

August 24, 2014




Resmed

ResMed Wins Initial Decision in ITC Patent Infringement Action

Judge Finds Nine BMC Products Infringe ResMed Patents

Judge Recommends Excluding U.S. Sale of BMC Masks and BMC Humidifier

SYDNEY and SAN DIEGO, Aug. 24, 2014 /PRNewswire/ -- An administrative law judge at the International Trade Commission (ITC) ruled Friday August 22 in a patent infringement case brought by ResMed (NYSE: RMD) against Chinese medical device manufacturer BMC Medical Co., Ltd., that each of nine BMC products named in the action infringes one or more ResMed patents. As a result, ITC Judge Thomas Pender recommended that the ITC ban BMC and its U.S. distributor, 3B Medical, from importing or selling any of the infringing BMC products in the United States. Judge Pender also recommended a cease and desist order that would enjoin BMC and 3B from selling, advertising, marketing, storing or testing the infringing products in the United States. ResMed is the innovation leader and pioneer in designing and manufacturing devices for the treatment of sleep-disordered breathing.



ResMed

*Changing lives
with every breath*

Judge Pender found that BMC's InH2 humidifier, as well as original and redesigned versions of the following BMC masks infringe ResMed's patents:

- iVolve nasal mask
- iVolve N2 nasal mask
- Willow nasal pillows mask
- iVolve full face mask

"The Judge's decision is not just a victory for ResMed and the product innovation that is core to our brand, but it's also a win for patients who deserve high quality, comfortable care," said David Pendarvis, ResMed chief administrative officer and global general counsel. "We will continue innovating and continue protecting our intellectual property anywhere we identify infringement."

About ResMed:

ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:

For News Media

Gretchen Griswold
Director, Global Corporate Communications
O: 858-836-6789
news@resmed.com

For Investors

Agnes Lee
Senior Director, Investor Relations
O: 858-836-5971
investorrelations@resmed.com

Logo - <https://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a>

SOURCE ResMed